Chapter 6 │ Page 215 37. Marin, D., et al., Safety, e icacy and determinants of response of allogeneic CD19specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nature Medicine, 2024. 30(3): p. 772-784. 38. Liu, E., et al., Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine, 2020. 382(6): p. 545-553. 39. Van den Eynde, A., et al., IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. Journal of Hematology & Oncology, 2024. 17(1): p. 8. 40. Luo, J. and X. Zhang, Challenges and innovations in CAR-T cell therapy: a comprehensive analysis. Front Oncol, 2024. 14: p. 1399544. 41. Peng, L., et al., CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cellular & Molecular Immunology, 2024. 21(10): p. 1089-1108. 42. Castiello, L., et al., Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe. Cancers (Basel), 2022. 14(21). 43. Lyu, C., et al., Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term E icacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk. Front Oncol, 2021. 11: p. 706087. 44. Holtermann, A., et al., Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors. BioDrugs, 2024. 38(5): p. 611-637. 45. Yusupov, M., et al., Oxidative damage to hyaluronan–CD44 interactions as an underlying mechanism of action of oxidative stress-inducing cancer therapy. Redox Biology, 2021: p. 101968. 46. Xing, S. and L. Ferrari de Andrade, NKG2D and MICA/B shedding: a 'tag game' between NK cells and malignant cells. Clin Transl Immunology, 2020. 9(12): p. e1230. 47. Ghadially, H., et al., MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue. Br J Cancer, 2017. 116(9): p. 1208-1217. 48. Bald, T., et al., The NK cell–cancer cycle: advances and new challenges in NK cell– based immunotherapies. Nature Immunology, 2020. 21(8): p. 835-847. 49. Borst, L., S.H. van der Burg, and T. van Hall, The NKG2A–HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment. Clinical Cancer Research, 2020. 26(21): p. 5549-5556. 50. Myers, J.A., et al., Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion. JCI Insight, 2022. 7(15). 51. Neo, S.Y., et al., CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. J Clin Invest, 2020. 130(3): p. 1185-1198. 52. Zhang, Q., et al., Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol, 2018. 19(7): p. 723-732. 53. Ziegler, A.E., et al., The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56(bright) NK cells. Front Immunol, 2023. 14: p. 1117320.
RkJQdWJsaXNoZXIy MTk4NDMw